Replacement Therapy with Virus-Inactivated Clotting Factor Concentrates in Patients with Severe Hemophilia in Heidelberg

Rainer Zimmermann; Christian Uhle; Angela Huth-Kühne

doi:10.1055/s-2002-30199

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2002; 28(S1): 075-078
DOI: 10.1055/s-2002-30199

Replacement Therapy with Virus-Inactivated Clotting Factor Concentrates in Patients with Severe Hemophilia in Heidelberg

Rainer Zimmermann, Christian Uhle, Angela Huth-Kühne

Kurpfalzkrankenhaus and Hemophilia Center and the SRH Group, Heidelberg, Germany

Abstract

Full Text

References

REFERENCES

1 Beeson P B. Jaundice occurring one to four months after transfusion of blood or plasma: report of seven cases. JAMA . 1943; 121 1332-1334
2 Kasper C K, Kipnis S A. Hepatitis and clotting-factor concentrates. JAMA . 1972; 221 510
3 Mannucci P M, Capitanio A, del Nino E. Symptomatic liver disease in haemophiliacs. J Clin Pathol . 1975; 28 620-624
4 Schimpf K, Zimmermann K. Hepatitishäufigkeit, serologische Befunde und Leberhistologie nach Therapie schwerer hämorrhagischer Diathesen mit Gerinnungsfaktorenkonzentraten. In: Schimpf K, ed. Fibrinogen, Fibrin and Fibrin Glue Side Effects of Therapy with Clotting Factor Concentrates Stuttgart: Schattauer Verlag 1980: 299-308
5 Hasiba U W, Spero J A, Lewis J H. Chronic liver dysfunction in multitransfused haemophiliacs. Transfusion . 1977; 17 490
6 Preston F E, Jarvis L M, Makris M. Heterogeneity of hepatitis C virus genotypes in haemophilia: relationship with chronic liver disease. Blood . 1995; 85 1259-1262
7 Makris M, Preston F E, Triger D R. The natural history of chronic liver disease in haemophilia: more rapid progression relates to age and mild disease. Br J Haematol (Abst) . 1992; 81(Suppl 1) 72
8 Zeuzem S, Roth W K, Herrmann G. Virus hepatitis C. Z Gastroenterol . 1995; 33 117-132
9 Simmonds P, Holmes E C, Cha T A. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol . 1993; 74 2391
10 Linnen J, Wages Jr J, Zhang-Keck Z Y. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science . 1996; 271 505-508
11 Dille B J, Surowy T K, Gutierrez R A. An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis . 1997; 175 458-461
12 Tacke M, Kiyosawa K, Stark K. Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet . 1997; 349 318-320
13 Kühnl P, Seidl S, Stangel W. Antibody to hepatitis C virus in German blood donors. Lancet . 1989; 2 324
14 Leary T P, Muerhoff A S, Simons J N. Consensus oligonucleotide primers for the detection of GB virus C in human cryptogenic hepatitis. J Virol Methods . 1996; 56 97-103
15 Heimburger N, Schwinn H, Mauler R. Faktor VIII-Konzentrat-hepatitissicher: Fortschritte in der Behandlung der Hämophilie A. Die gelben Hefte . 1980; 20 165-174
16 Mannucci P M, Schimpf K, Brettler D W, and the international study group. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. Ann Intern Med . 1990; 113 27-32